Detalles de la búsqueda
1.
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Cell
; 172(3): 578-589.e17, 2018 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373830
2.
Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
J Biol Chem
; 287(22): 18551-61, 2012 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-22493445
3.
A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
J Pharmacol Exp Ther
; 341(3): 702-8, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22414855
4.
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.
Am J Pathol
; 176(4): 1927-40, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20185574
5.
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
J Clin Invest
; 116(10): 2610-21, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17016557
6.
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Clin Cancer Res
; 14(22): 7272-83, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19010843
7.
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Cancer Res
; 66(3): 1434-45, 2006 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16452199
8.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Magn Reson Imaging
; 25(3): 319-27, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17371720
9.
Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
Cancer Res
; 65(20): 9253-60, 2005 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16230386
10.
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Mol Cancer Ther
; 5(7): 1774-82, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16891463
11.
Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.
Neoplasia
; 7(9): 847-53, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16229807
12.
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Drug Discov Today
; 16(23-24): 1052-60, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21875682
13.
Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor.
Ultrasound Med Biol
; 37(6): 909-21, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21531499
14.
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Cancer Res
; 71(4): 1362-73, 2011 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21212415
15.
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Cancer Res
; 70(24): 10090-100, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20952508
16.
Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Cancer Res
; 70(24): 10243-54, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21159645
17.
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Cancer Res
; 69(10): 4527-36, 2009 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19401451
18.
The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Mol Cancer Ther
; 10(11): 2015, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22072801
19.
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
Am J Physiol Heart Circ Physiol
; 290(2): H547-59, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16172161
20.
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
J Magn Reson Imaging
; 22(4): 511-9, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16161072